蛋白质治疗市场规模、份额、成长分析（按类型、应用、最终用户、功能和地区）- 产业预测，2025 年至 2032 年

2023 年蛋白质治疗市场规模价值 2,425.8 亿美元，预计将从 2024 年的 2,571.3 亿美元成长到 2032 年的 4,098.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.0%。

世界人口老化导致慢性病发病率上升，推动了对有效蛋白质疗法的需求，特别是对抗糖尿病、自体免疫疾病和癌症等疾病。与传统的小分子药物不同，生技药品，尤其是单株抗体，因其功效显着、副作用小、标靶特异性强而越来越受欢迎。蛋白质工程和生物技术的进步进一步加强了这个市场，重点是融合蛋白和双特异性抗体等下一代生技药品的创新。此外，使用单株抗体的个人化癌症治疗对于精准治疗变得越来越重要。此外，由于全球范围内鼓励对罕见疾病进行研究的倡议，蛋白质替代疗法 (PRT) 受到越来越多的关注，随着原始生技药品的专利到期到期，生物仿製药的出现扩大了治疗选择。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

蛋白质治疗市场规模（按类型）

• 市场概况
• 单株抗体
• 胰岛素
• 融合蛋白
• 人体生长荷尔蒙
• 促红血球生成素
• 干扰素

蛋白质治疗市场规模（按应用）

• 市场概况
• 癌症
• 代谢紊乱
• 免疫系统疾病
• 血液系统疾病
• 癌症
• 荷尔蒙失调
• 遗传性疾病
• 其他的

蛋白质治疗市场规模（按最终用户划分）

• 市场概况
• 製药公司
• 医疗服务供应商
• 研究组织
• 学术研究所

蛋白质治疗市场规模（按功能划分）

• 市场概况
• 疫苗
• 酵素与调节
• 蛋白质诊断

蛋白质治疗药物市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Johnson & Johnson（United States）
• Roche（Switzerland）
• Merck & Co.（United States）
• Pfizer（United States）
• AbbVie（United States）
• Sanofi（France）
• AstraZeneca（United Kingdom）
• Novartis（Switzerland）
• Bristol-Myers Squibb（United States）
• Abbott Laboratories（United States）
• GlaxoSmithKline（United Kingdom）
• Novo Nordisk（Denmark）
• Eli Lilly and Company（United States）
• Amgen（United States）
• Gilead Sciences（United States）
• Biogen（United States）
• Bayer（Germany）
• Takeda Pharmaceutical Company（Japan）
• CSL Behring（Australia）
• Teva Pharmaceutical Industries（Israel）

结论和建议

Protein Therapeutics Market size was valued at USD 242.58 billion in 2023 and is poised to grow from USD 257.13 billion in 2024 to USD 409.83 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The rising prevalence of chronic diseases, driven by an ageing global population, is fueling demand for efficient protein therapeutics, particularly to address conditions like diabetes, autoimmune disorders, and cancer. Unlike traditional small-molecule drugs, biologics, especially monoclonal antibodies, are gaining popularity due to their efficacy, fewer side effects, and targeted specificity. Advancements in protein engineering and biotechnology are further enhancing this market, with a focus on innovating next-generation biologics such as fusion proteins and bispecific antibodies. Moreover, tailored cancer therapies utilizing monoclonal antibodies are increasingly vital for precise treatment. In addition, protein replacement therapies (PRTs) are receiving significant attention, spurred by global initiatives encouraging research into rare diseases, alongside the emergence of biosimilars as original biologics' patents expire, broadening therapeutic options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Protein Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Protein Therapeutics Market Segments Analysis

Global Protein Therapeutics Market is segmented by Type, Application, End User, Function and region. Based on Type, the market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Human Growth Hormone, Erythropoietin and Interferon. Based on Application, the market is segmented into Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical companies, Healthcare Service Providers, Research Organizations and Academic Research Institutes. Based on Function, the market is segmented into Vaccines, Enzymatic and Regulatory and Protein Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Protein Therapeutics Market

The Protein Therapeutics market is significantly driven by the rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, which are becoming increasingly widespread globally. This surge in chronic illnesses is a primary catalyst for the growing demand for innovative protein-based treatments, such as biologics and monoclonal antibodies. These advanced therapeutic options offer targeted treatment capabilities, allowing for more effective management of complex medical conditions while minimizing side effects. As healthcare providers seek to address these pressing health issues, the reliance on protein therapeutics continues to expand, shaping the future of medical treatments and improving patient outcomes.

Restraints in the Protein Therapeutics Market

Despite the effectiveness of protein therapeutics, several factors hinder their widespread adoption. Chief among these is the high cost associated with these treatments, which renders them inaccessible to numerous patients. Additionally, inadequate insurance coverage complicates the financial landscape, as reimbursement levels vary significantly across different regions. This variability particularly affects patients in emerging markets, where affordability becomes a major barrier. Such economic challenges ultimately restrict market growth, limiting the potential of protein therapeutics to reach those who could benefit most from them, thereby impeding progress in this vital healthcare sector.

Market Trends of the Protein Therapeutics Market

The Protein Therapeutics market is experiencing a significant upward trend, fueled by the rising demand for personalized medicine that tailors treatments to individual genetic profiles. This shift enhances treatment efficacy while minimizing adverse effects, thereby attracting a larger patient base, particularly for oncology and autoimmune disorders. The increased focus on targeted biologics and advanced protein therapies not only caters to the specific needs of patients but also drives innovation in drug development. As healthcare providers embrace personalized approaches, investment in research and technology for protein-based therapeutics will likely intensify, positioning this market for substantial growth and advancement in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Protein Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Human Growth Hormone
• Erythropoietin
• Interferon

Global Protein Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Cancer
• Metabolic Disorders
• Immunologic Disorders
• Hematological Disorders
• Cancer
• Hormonal Disorders
• Genetic Disorders
• Others

Global Protein Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical companies
• Healthcare Service Providers
• Research Organizations
• Academic Research Institutes

Global Protein Therapeutics Market Size by Function & CAGR (2025-2032)

• Market Overview
• Vaccines
• Enzymatic and Regulatory
• Protein Diagnostics

Global Protein Therapeutics Market Size & CAGR (2025-2032)

• North America (Type, Application, End User, Function)
  • US
  • Canada
• Europe (Type, Application, End User, Function)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End User, Function)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End User, Function)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End User, Function)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations